Program – WBMT 2025

WBMT 2025 - Program

The symposium features a comprehensive two-day program covering the entire spectrum of cellular therapy.

Global Landscape of Cellular Therapies:
Presentations on CAR-T therapies from China, Southeast Asia, Japan, South Korea, Latin America, India, and developed countries.
Establishing a CAR-T Program:
Expert guidance on the essential clinical and laboratory elements required to set up a successful CAR-T program.
Advances in CAR-T Manufacturing:
Exploring innovative approaches like point-of-care and low-cost manufacturing from experiences in Barcelona, India, and Brazil.
Regulatory and Accreditation:
An in-depth look at worldwide regulatory frameworks, harmonization efforts by the WHO, and inspection and accreditation processes.
Beyond CAR-T:
Sessions dedicated to the role of gene therapy in non-malignant disorders such as sickle cell disease, thalassemia, and haemophilia.
Future Directions:
A look into the expanding landscape for CAR-T therapies, including their application for autoimmune diseases, T-cell malignancies, and myeloid malignancies.

Inaugural Program:
Welcome messages from WBMT, Ramaiah Medical College and WHO representatives.
Session I: Country Presentations:
A global overview of the landscape of CAR-T and other cellular therapies.
Session II: Setting up a CAR-T Program:
A framework for the clinical and laboratory aspects of program delivery.
Session III: The Role of HCT in the CAR-T Era:
Discussions on the current role of hematopoietic cell transplants for ALL, Myeloma, and B-cell Lymphomas.
Session IV: Current Advances in HCT:
Updates on conditioning regimens, GvHD prevention and therapies, and management of CMV.
Session V: Management of CAR-T Complications:
Focus on managing cytopenia, CRS, ICANS, and other neurologic or long-term complications.

Session VI: CAR-T Manufacturing:
Showcasing experiences in point-of-care and low-cost manufacturing from across the globe.
Session VII: Training and Organizational Issues:
Addressing the training needs for the healthcare team and operational changes with increasing CAR-T utilization.
Session VIII: Optimal Apheresis Product:
Delving into parameters and quality criteria for achieving the best starting material.
Session IX:
Regulatory Aspects, Biovigilance, and Accreditation: Navigating the complex regulatory and accreditation landscape for cellular therapies.
Session X:
Moving Beyond CAR-T: Exploring the expanding role of gene therapy in non-malignant hematological disorders.
Session XI:
Expanding the Landscape for CAR-T Therapies: Discussing the application of CAR-T cells in autoimmune diseases and other malignancies.